25 completed, 20 recruiting, 11 not yet recruiting, 11 terminated. 83 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) QLS7305 Injection - IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-08-10 | 2026-07-28 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy HRS-5965 Capsules - Primary IgA Nephropathy | Phase 2 | Recruiting | Chengdu Suncadia Medicine Co., Ltd. | 380 | 2026-07-06 | 2026-07-22 |
| SLN12140 in Adult Participants With IgA Nephropathy in China SLN12140, Placebo - IgA Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Linno Pharmaceuticals, Inc. | 48 | 2026-05-29 | 2026-04-28 |
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| A Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101 - IgA Nephropathy | Phase 2 | Recruiting | Jade Biosciences, Inc. | 30 | 2026-05-19 | 2026-10-30 |
| A Study to Assess the Effects of Zigakibart on IgA Nephropathy. zigakibart - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 32 | 2026-03-26 | 2026-10-21 |
| Efficacy and Safety Study of HS-10542 for IgA Nephropathy HS-10542 High Dose, HS-10542 Low Dose, Placebo - IgAN, Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 90 | 2026-03-17 | 2026-03-16 |
| A Study of SHR-2173 in Participants With Primary IgA Nephropathy SHR-2173 injection, Placebo - Primary IgA Nephropathy | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 84 | 2026-03-09 | 2026-05-13 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis KP104 - Glomerulonephritis | Phase 2 | Recruiting | Kira Pharmacenticals (US), LLC. | 52 | 2025-12-01 | 2026-11-03 |
| A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy RG002C0106, placebo subcutaneous administration - IgA Nephropathy (IgAN) | Phase 2 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 30 | 2025-09-08 | 2026-10-13 |
| Study of CM313 in Subject With IgA Nephropathy CM313, Placebo - IgA Nephropathy | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 106 | 2025-09-01 | 2025-09-19 |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease ADX-038 Dose Level 2, ADX-038 Dose Level 1 - IgAN, C3G | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 45 | 2025-08-28 | 2026-10-20 |
| A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy HSK39297 200mgQD, HSK39297 300mgQD - IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 73 | 2025-08-25 | 2026-06-01 |
Showing 20 of 83. Sign in to see all of them.
Kidney Diseases (12) · Glomerulonephritis (8) · Proteinuria (8) · Lupus Nephritis (6) · Diabetic Nephropathies (5) · Autoimmune Diseases (4) · Glomerulonephritis, Membranous (4) · Glomerulosclerosis, Focal Segmental (4) · Immune System Diseases (4) · Urologic Diseases (4) · Glomerulonephritis, Membranoproliferative (3) · Nephritis (3) · Nephrosis, Lipoid (3) · Diabetes Mellitus (2)
Female Urogenital Diseases (83) · Female Urogenital Diseases and Pregnancy Complications (83) · Male Urogenital Diseases (83) · Urogenital Diseases (81) · Nephritis (80) · Autoimmune Diseases (79) · Immune System Diseases (79) · Urologic Diseases (79) · Glomerulonephritis (75) · Kidney Diseases (71) · Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (9) · Connective Tissue Diseases (8) · Skin and Connective Tissue Diseases (8) · Urination Disorders (8)
TACI receptor-IgG Fc fragment fusion protein (4) · Mycophenolic Acid (3) · Prednisolone (3) · sparsentan (3) · telitacicept (3) · Atrasentan (2) · Prednisone (2) · avacopan (2) · felzartamab (2) · fostamatinib (2) · AMG623 peptibody (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Anti-Inflammatory Agents (1) · Budesonide (1) · Cyclophosphamide (1)
Novartis Pharmaceuticals (6) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Vera Therapeutics, Inc. (3) · ADARx Pharmaceuticals, Inc. (2) · Alexion Pharmaceuticals, Inc. (2) · Biogen (2) · Calliditas Therapeutics AB (2) · Chengdu Suncadia Medicine Co., Ltd. (2) · Guangdong Hengrui Pharmaceutical Co., Ltd (2) · Haisco Pharmaceutical Group Co., Ltd. (2) · Keymed Biosciences Co.Ltd (2) · RemeGen Co., Ltd. (2) · Rigel Pharmaceuticals (2) · Sun Yat-sen University (2) · Travere Therapeutics, Inc. (2)
China (34) · United States (33) · United Kingdom (20) · South Korea (17) · Australia (15) · Spain (15) · Taiwan (12) · Germany (11) · Malaysia (10) · Italy (9) · Hong Kong (8) · Japan (8) · Thailand (7) · Brazil (6) · Canada (6)
Connie L Davis, MD (2) · Jicheng Lv (2) · Radko Komers, MD, PhD (2) · Zongpei Jiang, M.D. & Ph.D. (2) · Alex Mercer, PhD (1) · Arezoo Mirad (1) · Arezoo Mirad, MD (1) · Asher Schachter, M.D. (1) · Carla M Nester, MD, MSA, FASN (1) · Chee Kay Cheung, MBChB PhD (1) · Eric Michael, MD (1)
PMID 38299639, PMID 26032537, PMID 37528520, PMID 39899371, PMID 40938675, PMID 17699247, PMID 23977072, PMID 28363480, PMID 30177021, PMID 31907076, PMID 34124781, PMID 35062886, PMID 37036696, PMID 37254256, PMID 37772889, PMID 37916620, PMID 38008160, PMID 38724717, PMID 39331470, PMID 39455063, PMID 39462310, PMID 40444214, PMID 40465397, PMID 40482854, PMID 40581166, PMID 41408192, PMID 41442197, PMID 41443406, PMID 41904616, PMID 42275148, PMID 42384439
2018 (3), 2014 (2), 2023 (2), 2005 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), R01DK049368 (1)